Yang Shaokang, Yang Xiaotong, Zhu Weiyan, Luo Chongda, Yan Xintong, Li Wei, Cao Ruiyuan, Zhong Wu
National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Virology. 2025 Feb;603:110334. doi: 10.1016/j.virol.2024.110334. Epub 2024 Nov 29.
Zika virus (ZIKV) is a mosquito-borne, positive-stranded RNA virus, ZIKV infection during pregnancy threatens pregnancy and fetal health, and it remains a global health threat, there are no clinically approved vaccines or antiviral drugs for the treatment of ZIKV infection. VV116 is an oral drug candidate of nucleoside analog against SARS-CoV-2 that has demonstrated a satisfactory safety and tolerability in healthy subjects. Our study shows for the first time that VV116 has potent activity against ZIKV. We verified that VV116 can inhibit the RNA and protein level of ZIKV in vitro. Importantly, treatment with VV116 significantly enhanced survival and provided protection in ZIKV-infected ICR mice. VV116 acted at the replication stage of viral infection cycle, and exhibited reasonable inhibition of ZIKV replicons. Collectively, the in vitro and in vivo anti-ZIKV activity of VV116 suggests that it is a promising anti-ZIKV drug candidate.
寨卡病毒（ZIKV）是一种由蚊子传播的正链RNA病毒，孕期感染寨卡病毒会威胁妊娠和胎儿健康，它仍是全球健康威胁，目前尚无临床批准的用于治疗寨卡病毒感染的疫苗或抗病毒药物。VV116是一种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的核苷类似物口服候选药物，已在健康受试者中显示出令人满意的安全性和耐受性。我们的研究首次表明VV116对寨卡病毒具有强效活性。我们证实VV116在体外可抑制寨卡病毒的RNA和蛋白质水平。重要的是，用VV116治疗可显著提高感染寨卡病毒的ICR小鼠的存活率并提供保护。VV116作用于病毒感染周期的复制阶段，并对寨卡病毒复制子表现出合理的抑制作用。总体而言，VV116的体外和体内抗寨卡病毒活性表明它是一种有前景的抗寨卡病毒候选药物。
